28,008 Shares in Repligen Corporation $RGEN Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. purchased a new stake in Repligen Corporation (NASDAQ:RGEN) during the second quarter, HoldingsChannel.com reports. The firm purchased 28,008 shares of the biotechnology company’s stock, valued at approximately $3,484,000.

Other hedge funds have also recently bought and sold shares of the company. DekaBank Deutsche Girozentrale boosted its holdings in shares of Repligen by 1.0% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock worth $961,000 after acquiring an additional 80 shares during the period. Alliance Wealth Advisors LLC UT lifted its holdings in Repligen by 2.5% during the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 89 shares during the last quarter. Drive Wealth Management LLC lifted its holdings in Repligen by 2.5% during the 2nd quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 93 shares during the last quarter. ProShare Advisors LLC boosted its stake in Repligen by 4.3% in the 2nd quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 96 shares during the period. Finally, Louisiana State Employees Retirement System grew its holdings in Repligen by 0.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 14,700 shares of the biotechnology company’s stock valued at $1,828,000 after buying an additional 100 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Repligen

In related news, COO James Bylund sold 2,191 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the sale, the chief operating officer directly owned 21,520 shares of the company’s stock, valued at $3,254,039.20. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Anthony Hunt sold 25,000 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total value of $3,922,000.00. Following the transaction, the director directly owned 100,743 shares of the company’s stock, valued at approximately $15,804,561.84. The trade was a 19.88% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 49,382 shares of company stock worth $7,676,802. Corporate insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $166.52 on Thursday. The firm has a 50 day moving average of $152.19 and a 200-day moving average of $132.61. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $9.37 billion, a PE ratio of 8,330.17, a PEG ratio of 3.74 and a beta of 1.11.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The business had revenue of $188.81 million for the quarter, compared to analysts’ expectations of $181.23 million. During the same period last year, the firm posted $0.43 earnings per share. The firm’s quarterly revenue was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities research analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RGEN shares. Jefferies Financial Group set a $160.00 target price on Repligen and gave the stock a “hold” rating in a report on Tuesday, October 28th. HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. HSBC initiated coverage on shares of Repligen in a report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price objective for the company. Canaccord Genuity Group raised their target price on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. Finally, Evercore ISI lifted their price target on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and an average price target of $173.85.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.